FDA approves first gene therapy for hemophilia B

12/01/2022

On November 22, 2022, the FDA approved Hemgenix^®, an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with Hemophilia B (congenital Factor IX deficiency) who:

• Currently use Factor IX (FIX) prophylaxis therapy, or
• Have current or historical life-threatening hemorrhage, or
• Have repeated, serious spontaneous bleed episodes

The IHTC has had the most hands-on experience with gene therapy for individuals with hemophilia in Indiana. The IHTC staff have received extensive training and are knowledgeable about all aspects of gene therapy with Hemgenix®, including preparation for treatment, administration of the therapy, and close monitoring once it has been given. As with all new therapies, the IHTC will be mailing a letter to our patients with more detailed information.

If you have any questions or want more information about Hemgenix^®, call the center at 1-877-CLOTTER.

LEARN MORE ABOUT HEMGENIX^®